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A rare case of severe disseminated histoplasmosis in a
7-year-old boy with apparently normal immune function is
described. Current recommendations for diagnostic
investigations, monitoring and the treatment of this
disease with amphotericin B and itraconazole are
reviewed.
S Afr Med J 1998; 88: 270-271.
Histoplasma capsulatum is a dimorphic fungus, the yeast
form of which parasitises mammalian macrophages. The
organism is more prevalent where heavy accumulations of
bat or avian excrement are found. Pigeon roosts, chicken
houses and sites frequented by bats such as caves, attics
and hollow trees in endemic areas, are therefore most apt to
be point sources. ' In South Africa, this infection is rare and
most reported cases have been related to cave exposure.'·5
Human infection has a number of different clinical
pictures: acute pulmonary histoplasmosis (the most
common form), chronic pulmonary histoplasmosis and
disseminated histoplasmosis. The disseminated form is
relatively uncommon. Two groups of susceptible hosts are
recognised: infants with immature immunity and
immunosuppressed individuals. Very rarely, infection occurs
in patients with apparently normal immune function."·
Disseminated histoplasmosis is included among the
opportunistic infections that can occur in AIDS and in recent
years most reported cases have been AIDS-related. 7•• Few
cases of disseminated histoplasmosis have been reported in
southern Africa and only 2 of these were in children."'13 The
first was a 13-year-old boy from Zimbabwe in 1951 and the
second a successfully treated 10-year-old boy from
Kwazulu-Natal in 1976.
This report presents a third paediatric case and reviews
the current diagnostic tests and management.
Case report
A 7-year-old black African boy presented at Frere Hospital in
East London with fever, lassitude and weight loss. He had
been a healthy child prior to the onset of this illness with no
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previous history of recurrent infections or major illness.
There was no history of exposure to caves. He lived on a
rural farm and had been exposed to a large number of
chickens. Examination showed him to be wasted and pale
with diffuse lymphadenopathy and splenomegaly. The blood
count showed anaemia and thrombocytopenia and he
underwent a bone marrow biopsy and aspiration to exclude
a possible underlying haematological malignancy. This
showed a heavy infiltration of Histoplasma capsulatum. This
finding was confirmed on cultures done at the South African
Institute for Medical Research in Johannesburg and the
organism was reported to be sensitive to amphotericin B. An
enzyme-linked immunosorbent assay for HIV was negative.
A Mantoux skin test was negative and a chest radiograph
showed bilateral parahilar infiltrates.
The patient underwent 3 weeks of treatment with
amphotericin B and was then put on ketoconazole. Two
months later he deteriorated and was re-started on
amphotericin B. After a further period of treatment he was
referred to Red Cross Children's Hospital because of
marked deterioration and the development of septic arthritis.
At the time of transfer he had received a total of 22 mg/kg
amphotericin B.
On admission he was extremely ill with severe wasting
and diffuse septic arthritis affecting the ankles, knees,
elbows, wrists and the costochondral junctions.
Radiographs showed evidence of severe widespread
osteitis. His skin, especially on his face, showed numerous
raised, umbilicated lesions. He was anaemic with mild
disseminated intravascular coagulation (DIG), and had
significantly impaired renal function (serum creatinine
concentration 192 I-lmoVI) and hypokalaemia (2.9 mmol/I).
A repeat bone marrow examination confirmed
histoplasmosis on microscopy and culture. Blood culture
grew a Staphylococcus aureus resistant to cloxacillin and
erythromycin. HIV tests were again negative.
No evidence of immune deficiency could be found on
investigation. The patient had a polyclonal
hypergammaglobulinaemia with normal antibody response
to tetanus immunisation. T-cell response to mitogen and
antigens and T-cell subset distribution were normal. The
results of bactericidal assays for candida and
staphylococcus, chemotaxis studies and complement
assays were all normal.
He underwent surgical drainage procedures of the right
wrist, right elbow, both ankles and the right tibia. Material
drained from the joints cultured both Histoplasma
capsulatum and Staphylococcus aureus and biopsy material
from all sites (synovium and bone) showed many
histoplasma organisms on methenamine silver stain. He was
started on liposomal amphotericin and vancomycin.
Liposomal amphotericin 3 mg/kg/day for 40 days was
followed by 6 mg/kg/day for a further week; this regimen
was chosen because of deteriorating renal function.
Vancomycin was chosen because the staphylococcus was
resistant to cloxacillin. His renal function and hypokalaemia
returned to normal within a week on the above treatment.
The patient's general condition showed a slow but steady
improvement with his fever settling and good weight gain.
Repeat bone marrow examination after 14 days of liposomal
amphotericin still showed a heavy fungal infiltrate and the
organism was cultured after about 10 days. Repeat bone
Art c e s
marrow examination after 34 days of treatment showed the
same picture and prompted the increase of the liposomal
amphotericin dose.
At this point, on the advice of Professor L J Wheat of
Indiana University Medical School, treatment was changed
to oral itraconazole 5. mg/kg/day with monitoring of the
disease by means of histoplasma antigen levels, done by
the histoplasma reference laboratory at Indiana University
School of Medicine. The initial antigen levels were markedly
raised in both urine (9.8 units) and serum (8.7 units). The
patient progressed very well on itraconazole treatment and
was discharged (nearly 9 months from his initial diagnosis)
for outpatient treatment and follow-up. It was planned to
give itraconazole 5. mg/kg/day until the histoplasma antigen
levels were below 2 units. Repeat immune function tests
prior to discharge were again normal.
Repeat measurement of histoplasma antigen levels over
the next 18 months showed them to be persistently
elevated, despite a significant decline in the first few
months. Repeat bone marrow aspiration after 1 year on
treatment showed a persistence of yeasts. The patient has
been continued on long-term itraconazole and remains
clinically well on treatment.
Discussion
The known risk factors for disseminated histoplasmosis
include immunosuppression and extremes of age (infants
and the elderly)."'· In this patient, none of the known risk
factors could be identified and immune function tests
showed no abnormality. Goodwin et al.· in a report of 102
cases of disseminated histoplasmosis, described 20
patients who had no demonstrable immune defect and
remained well following treatment. He postulated a
'temporary impairment of immunological control'. Kurita et
al." have shown a resistance of the yeast form of
Histoplasma capsulatum to killing by human neutrophils,
possibly as a result of evasion of the toxic products of the
oxidative burst by an ill-defined mechanism.
The source of this patient's infection is not known, a
history of any cave exposure being denied, but he does
have a history of exposure to chickens. A limited number of
non-cave-related infections are being recognised in
specimens from patients in the Eastern Cape (K Klugman,
SAIMR, Johannesburg - personal communication).
Two of the clinical features in this case, the skin lesions
and particularly the severe bone and joint involvement, are
also unusual although the concomitant staphylococcal
infection contributed to the severe skeletal changes. The
patient's inability to clear the infecfion could be due to
dysfunction of his immune system that our tests failed to
identify.
Disseminated histoplasmosis can be diagnosed by
histological appearance, fungal culture of blood or bone
marrow, serology or antigen detection.'·'· Histoplasma
antigen levels, done every 3 - 4 months, are useful in
monitoring both the initial response to treatment and
relapse, especially in immunocompromised patients.··'T.,.
Treatment with antifungal therapy is indicated in all
patients with disseminated histoplasmosis. Amphotericin B
is the drug of choice in severely ill patients and the
recommended total dose is 35 mg/kg.' The main problem is
drug toxicity. Goodwin et al.· in a series of patients treated
with amphotericin B reported that 40% failed to complete
the treatment course because of drug toxicity. Standard
amphotericin B is a colloidal complex with desoxycholate. In
patients unable to complete a course of treatment because
of toxicity a liposomal encapsulated preparation of
amphotericin is an alternative. This preparation carries much
lower toxicity but has two disadvantages: the extremely high
cost (relative to the standard preparation) and the fact that
larger doses may be necessary to achieve a biologically
equivalent effect.'9 Our patient tolerated a dose three times
the standard amphotericin B dose without toxicity, but the
response to treatment was very slow. It is impossible to say
whether this was caused by resistant disease or lower
biological activity of the liposomal amphotericin.
Following initial treatment with amphotericin B or,
alternatively, as a first-line drug in less ill patients, ongoing
treatment with itraconazole in a dose of 5 mgikgiday orally
has been recommended:O.2' Prolonged treatment, for a year
or more, may be necessary and the resolution or relapse of
the infection should be monitored with histoplasma antigen
levels. Ketoconazole has also been used but appears to be
less effective than itraconazole.".2O
In conclusion, a very rare case of disseminated
histoplasmosis has been described and the current
diagnostic tests and management have been reviewed.
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